Ionis Closes Strategic Collaboration With Biogen To Develop Drugs For Broad Range of Neurological Diseases; Biogen Paid Ionis $1B In Cash Including $625M For Purchase Of ~11.5M Shares Of Common Stock @ $54.34/Share And An Upfront Payment Of $375M
Benzinga Newsdesk